Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Accumulated Expenses (2020 - 2026)

Immuneering's Accumulated Expenses history spans 7 years, with the latest figure at $3.1 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 9.58% to $3.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.1 million, a 9.58% decrease, with the full-year FY2025 number at $7.8 million, up 57.69% from a year prior.
  • Accumulated Expenses came in at $3.1 million for Q1 2026, down from $7.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $7.8 million in Q4 2025, with the low at $48102.0 in Q2 2022.
  • Historically, Accumulated Expenses has averaged $3.9 million across 5 years, with a median of $3.8 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: crashed 98.55% in 2022 and later skyrocketed 4945.32% in 2023.
  • Year by year, Accumulated Expenses stood at $4.5 million in 2022, then grew by 14.95% to $5.2 million in 2023, then dropped by 3.88% to $5.0 million in 2024, then skyrocketed by 57.69% to $7.8 million in 2025, then crashed by 60.93% to $3.1 million in 2026.
  • Business Quant data shows Accumulated Expenses for IMRX at $3.1 million in Q1 2026, $7.8 million in Q4 2025, and $7.5 million in Q3 2025.